These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
174 related articles for article (PubMed ID: 33517325)
1. Synthesis and Evaluation of Antunes IF; Dost RJ; Hoving HD; van Waarde A; Dierckx RAJO; Samplonius DF; Helfrich W; Elsinga PH; de Vries EFJ; de Jong IJ J Nucl Med; 2021 Aug; 62(8):1140-1145. PubMed ID: 33517325 [TBL] [Abstract][Full Text] [Related]
2. In vivo imaging of brain androgen receptors in rats: a [(18)F]FDHT PET study. Khayum MA; Doorduin J; Antunes IF; Kwizera C; Zijlma R; den Boer JA; Dierckx RA; de Vries EF Nucl Med Biol; 2015 Jun; 42(6):561-9. PubMed ID: 25735222 [TBL] [Abstract][Full Text] [Related]
3. Specific Larimer BM; Dubois F; Bloch E; Nesti S; Placzek M; Zadra G; Hooker JM; Loda M; Mahmood U J Nucl Med; 2018 Oct; 59(10):1538-1543. PubMed ID: 29853654 [TBL] [Abstract][Full Text] [Related]
4. Pharmacokinetic assessment of the uptake of 16beta-18F-fluoro-5alpha-dihydrotestosterone (FDHT) in prostate tumors as measured by PET. Beattie BJ; Smith-Jones PM; Jhanwar YS; Schöder H; Schmidtlein CR; Morris MJ; Zanzonico P; Squire O; Meirelles GS; Finn R; Namavari M; Cai S; Scher HI; Larson SM; Humm JL J Nucl Med; 2010 Feb; 51(2):183-92. PubMed ID: 20080885 [TBL] [Abstract][Full Text] [Related]
7. Tumor localization of 16beta-18F-fluoro-5alpha-dihydrotestosterone versus 18F-FDG in patients with progressive, metastatic prostate cancer. Larson SM; Morris M; Gunther I; Beattie B; Humm JL; Akhurst TA; Finn RD; Erdi Y; Pentlow K; Dyke J; Squire O; Bornmann W; McCarthy T; Welch M; Scher H J Nucl Med; 2004 Mar; 45(3):366-73. PubMed ID: 15001675 [TBL] [Abstract][Full Text] [Related]
8. Imaging Androgen Receptors in Breast Cancer with Jacene H; Liu M; Cheng SC; Abbott A; Dubey S; McCall K; Young D; Johnston M; Van den Abbeele AD; Overmoyer B J Nucl Med; 2022 Jan; 63(1):22-28. PubMed ID: 34049982 [TBL] [Abstract][Full Text] [Related]
9. Fully-automated synthesis of 16β-(18)F-fluoro-5α-dihydrotestosterone (FDHT) on the ELIXYS radiosynthesizer. Lazari M; Lyashchenko SK; Burnazi EM; Lewis JS; van Dam RM; Murphy JM Appl Radiat Isot; 2015 Sep; 103():9-14. PubMed ID: 26046518 [TBL] [Abstract][Full Text] [Related]
10. Consecutive Prostate-Specific Membrane Antigen (PSMA) and Antigen Receptor (AR) PET Imaging Shows Positive Correlation with AR and PSMA Protein Expression in Primary Hormone-Naïve Prostate Cancer. Al Jalali V; Wasinger G; Rasul S; Grubmüller B; Wulkersdorfer B; Balber T; Mitterhauser M; Simon J; Hacker M; Shariat S; Egger G; Zeitlinger M J Nucl Med; 2023 Jun; 64(6):863-868. PubMed ID: 36657982 [TBL] [Abstract][Full Text] [Related]
12. 18F-RB390: innovative ligand for imaging the T877A androgen receptor mutant in prostate cancer via positron emission tomography (PET). Bertolini R; Goepfert C; Andrieu T; Nichols S; Walter MA; Frey FJ; McCammon JA; Frey BM Prostate; 2015 Mar; 75(4):348-59. PubMed ID: 25358634 [TBL] [Abstract][Full Text] [Related]
13. Synthesis and basic evaluation of 7α-(3-[ Okamoto M; Naka K; Ishiwata K; Shimizu I; Toyohara J Ann Nucl Med; 2017 Jan; 31(1):53-62. PubMed ID: 27680022 [TBL] [Abstract][Full Text] [Related]
14. Optimization of the preparation of fluorine-18-labeled steroid receptor ligands 16alpha-[18F]fluoroestradiol (FES), [18F]fluoro furanyl norprogesterone (FFNP), and 16beta-[18F]fluoro-5alpha-dihydrotestosterone (FDHT) as radiopharmaceuticals. Zhou D; Lin M; Yasui N; Al-Qahtani MH; Dence CS; Schwarz S; Katzenellenbogen JA J Labelled Comp Radiopharm; 2014 May; 57(5):371-7. PubMed ID: 24861984 [TBL] [Abstract][Full Text] [Related]
15. Fully automated synthesis of [(18) F]fluoro-dihydrotestosterone ([(18) F]FDHT) using the FlexLab module. Ackermann U; Lewis JS; Young K; Morris MJ; Weickhardt A; Davis ID; Scott AM J Labelled Comp Radiopharm; 2016 Aug; 59(10):424-8. PubMed ID: 27378195 [TBL] [Abstract][Full Text] [Related]
16. Androgen and Estrogen Receptor Imaging in Metastatic Breast Cancer Patients as a Surrogate for Tissue Biopsies. Venema CM; Mammatas LH; Schröder CP; van Kruchten M; Apollonio G; Glaudemans AWJM; Bongaerts AHH; Hoekstra OS; Verheul HMW; Boven E; van der Vegt B; de Vries EFJ; de Vries EGE; Boellaard R; Menke van der Houven van Oordt CW; Hospers GAP J Nucl Med; 2017 Dec; 58(12):1906-1912. PubMed ID: 28912144 [TBL] [Abstract][Full Text] [Related]
17. Synthesis and fluorine-18 radiolabeling of a phospholipid as a PET imaging agent for prostate cancer. Kwan KH; Burvenich IJG; Centenera MM; Goh YW; Rigopoulos A; Dehairs J; Swinnen JV; Raj GV; Hoy AJ; Butler LM; Scott AM; White JM; Ackermann U Nucl Med Biol; 2021 Feb; 93():37-45. PubMed ID: 33310350 [TBL] [Abstract][Full Text] [Related]
19. Report on the PET/CT Image-Based Radiation Dosimetry of [ McCall KC; Liu M; Cheng SC; Abbott A; Dubey S; Young D; Johnston M; Van den Abbeele AD; Overmoyer B; Jacene H J Nucl Med Technol; 2023 Sep; 51(3):204-210. PubMed ID: 37316304 [TBL] [Abstract][Full Text] [Related]
20. More advantages in detecting bone and soft tissue metastases from prostate cancer using Pianou NK; Stavrou PZ; Vlontzou E; Rondogianni P; Exarhos DN; Datseris IE Hell J Nucl Med; 2019; 22(1):6-9. PubMed ID: 30843003 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]